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Class IV-S versus class IV-G lupus nephritis: Clinical and
morphologic differences suggesting different pathogenesis.
Background. A recently proposed reclassification of lupus
nephritis divides class IV (diffuse proliferative) lupus nephri-
tis into those cases with predominantly segmental proliferative
lesions (class IV-S) and those with predominantly global pro-
liferative lesions (class IV-G). This report explores the validity
of this distinction and possible differences in pathogenesis be-
tween the 2 types of lesions.
Methods. Patients from a previously reported series of severe
lupus nephritis, with initial biopsies (Bx1) and control biopsies
(Bx2) at 6 months after induction therapy were reclassified ac-
cording to the newly proposed classification. From the original
series of 65 patients, 15 patients were reclassified as having class
IV-S lesions and 31 patients class IV-G lesions. Clinical data
at both biopsies and follow-up were available on all patients
selected.
Results. Patients with IV-G lesions had worse proteinuria,
lower serum hemoglobins, lower CH50s, and likely higher SCrs
(P = .06) and lower C3s (P = .08) than class IV-S patients. Serum
CH50 and C3 correlated negatively with severity of class IV-
G lesions, but not at all with class IV-S lesions. Patients with
class IV-G lesions had greater overall immune deposits and
subendothelial deposits on IF and greater hyaline deposits on
light microscopy. By contrast, class IV-S showed predominant
mesangial deposits and a much higher rate of glomerular fibri-
noid necroses (13.3 ± 15.3% vs. 5.6 ± 8.0% of viable glomeruli,
P = .03). Other distinctions included the fact that membra-
noproliferative features were found only in class IV-G lesions,
and glomerular monocyte/macrophages were much more fre-
quent in this group than in class IV-S lesions (1.77 ± 0.92 vs.
0.86 ± 0.77, P = .008). Finally, class IV-G frequently involved
all viable glomeruli (74.2% of cases), whereas segmental prolif-
erative lesions never did (P <.0001). Survivals from doubling of
SCr at 10 years did not differ between the 2 types at Bx1: 72.5%
segmental versus 60.4% global, P = .53. However, among those
with persistent lesions at Bx 2 (11 IV-S and 9 IV-G), there was
a dramatic difference in 10-year survivals between IV-S lesions
(63.6%) and IV-G lesions (0%), P = .08.
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Conclusion. There are definite clinical and morphologic dif-
ferences between class IV-S and IV-G lesions. Data suggest that
class IV-G lesions behave as an immune complex disease, hav-
ing positive correlations with extent of immune deposits and
negative correlations with serum complement levels, the model
traditionally assumed for lupus nephritis as a whole. However,
in class IV-S lesions, the presence of proportionally greater
glomerular fibrinoid necroses and lack of correlation with ex-
tent of immune deposits suggest that these lesions may have a
different pathogenesis.
A new classification of glomerulonephritis in systemic
lupus erythematosus has recently been proposed [1]. This
classification seeks to rectify some of the problems that
have arisen over the years with the World Health Organi-
zation classification, dating from 1982 and revised in 1995
[1]. The most important changes have come in class IV
lupus glomerulonephritis. Class IV, formerly called dif-
fuse proliferative lupus nephritis, by definition involving
more than 50% of glomeruli, has now been subdivided
into 2 subclasses according to whether the majority of
the lesions involve the glomeruli in segmental fashion
with some lobules involved and others spared (class IV-
S), as seen in Figure 1, or in a global fashion with the
majority or all of the tuft showing proliferative lesions
and deposits (class IV-G), as in Figure 2. This subdivision
comes in significant part as the result of a study by Najafi
et al [2], in which it was found that cases with “severe seg-
mental” glomerular lesions, involving greater than 50%
of glomeruli (the equivalent of class IV-S), actually had a
worse outcome at 10 years than those with those with dif-
fuse proliferative lesions involving the entire glomerular
tuft (the equivalent of class IV-G).
We evaluated the distinction between classes IV-S and
IV-G, reviewing the material from a previously studied
group of patients having initial and systematic 6-month
posttreatment induction biopsies [3–5]. The cases were
reclassified according to the new classification and the
previously gathered clinical and morphologic data was
reevaluated in light of the new classification. In our se-
ries, we found, contrary to the study of Najafi et al
[2], that there was no significant difference in survival
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Fig. 1. Class IV segmental proliferative lupus nephritis. Both glomeruli
show segmental lesions, with a large segmental fibrinoid necrosis in the
one on the left. PAS-Masson-silver stain, ×350 magnification.
between the patients with class IV-S and IV-G lesions at
the initial biopsy. However, at the control biopsy after
treatment, persistence of class IV-G lesions appeared to
be associated with a much worse survival than that for
patients who manifested class IV-S lesions at the second
biopsy. More importantly, there were significant clinical
and morphologic differences between the 2 subclasses,
suggesting that they may have a different pathogenesis.
METHODS
The cases restudied came from a group of 71 previously
reported patients from 4 Paris hospitals (Bichat, Brous-
sais, Henri Mondor, and St. Louis) entered in a treatment
protocol from the period 1986 to 1994, with initial biop-
sies and control biopsies at 6 months after induction treat-
ment with monthly cyclophosphamide boluses combined
with steroids or with steroids alone [3–5]. This material
was reviewed and reclassified according to the criteria in
the revised classification [1]. Fifty-five cases had initially
been diagnosed as diffuse proliferative lupus nephritis,
without a superadded membranous component. After re-
view of these 55 cases, 6 cases in which the initial diagnosis
had been made on paraffin-embedded frozen material,
and 3 cases with incomplete follow-up, were eliminated.
There remained 15 cases of class IV-S (Fig. 1) and 31 cases
of class IV-G (Fig. 2) lupus glomerulonephritis.
The patients retained for this study had an average
age of 35 ± 14 years, and were divided ethnically as fol-
lows: whites 63.3%, North African 17.4%, Asian 8.7%,
and black 10.9%. There were no significant differences in
ages, sex, or ethnic distribution between the 2 groups.
Specimens were processed by standard histologic and
immunofluorescence techniques as described previously
[3]. The following clinical parameters were evaluated
Fig. 2. Class IV global proliferative lupus nephritis. Both glomeruli
show uniform diffuse endocapillary proliferation. Masson trichrome
stain, ×350 magnification.
at the time of each biopsy: blood pressure, CH50, C3,
C4, anti-DNA antibodies (DNA), serum creatinine (SCr,
lmol/L), proteinuria (g/24h), and hematuria (rbc/mL),
hemoglobin, and platelets. The principal outcome param-
eter examined here was doubling of the initial serum cre-
atinine (CRX2) for 3 months or more. Also examined was
renal relapse, recrudescence of renal disease after an ini-
tial therapeutic response, as defined by a recent increase
of SCr by >50% with active urinary sediment and/or in-
crease in proteinuria to 3.5g/day or greater. Complete
follow-up data were available for all patients in this study.
Morphologic variables
The schema for evaluation of morphologic variables
has been reported in detail in another communication [3]
and is detailed in Table 1. Briefly, the method of grad-
ing morphologic lesions parallels that used by Austin
et al [6, 7], but adds consideration of tubular lesions and
immunofluorescence data. Also evaluated was the loca-
tion of glomerular deposits on IF as detailed previously
[4], with only definitely recognizable subendothelial and
subepithelial deposits being reported in this study. (Un-
fortunately, electron microscopy was not routinely avail-
able on these cases.)
All glomeruli in at least 1 section of every biopsy were
evaluated, with multiple sections evaluated in the in-
stance of biopsies containing less than 10 glomeruli. They
were classified according to the presence and distribution
(segmental vs. global) of proliferative lesions, fibrinoid
necroses, and scarring. Results were reported as percent-
ages of viable glomeruli. Totally sclerotic glomeruli were
counted separately and reported as a percentage of all
glomeruli present.
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Table 1. Components of biopsy index
Symbol Scale
Glomerular activity index (GAI)
Glomerular proliferation glprolif 0–3+
Polymorphonuclear leukocytes glpmn 0–3+
Karyorrhexis/Fibrinoid necrosis karyfib (0–3+) X2
Cellular crescents cresc (0–3+) X2
Hyaline deposits hyaldep 0–3+
Glomerular monocytes glmono 0–3+
Maximum 24
Tubulointerstitial activity index (TIAI)
Tubular cell pyknosis tubpyk 0–3+
Tubular nuclear ‘activation’ tubact 0–3+
Tubular cell necrosis tubnec 0–3+
Tubular cell flattening tubflat 0–3+
Macrophages in tubular lumens macrlum 0–3+
Epithelial cells in tubular lumens eplum 0–3+
Interstitial inflammation intinfl 0–3+
Maximum 21
Chronicity lesions index (CI)
Glomerulosclerosis glscl 0–3+
Glomerular scars gloscar 0–3+
Fibrous crescents fibcres 0–3+
Tubular atrophy tubatro 0–3+
Interstitial fibrosis intfib 0–3+
Maximum 15
Immunofluorescence index (IFI)
Glomerular capillary IF glcapif (0–4+) X6 antisera
Glomerular mesangial IF glmesif (0–4+) X6 antisera
Tubulointerstitial IF tubulif (0–4+) X6 antisera
Vascular IF vascif (0–4+) X6 antisera
Maximum 96
BiopsyIndex = GAI8 + TIAI7 + CLI5 + IF Index32 = Maximum12
Biopsy index is composed of each of the individual indices, normalized to 3
maximum by division by appropriate number of components.
Statistical analyses
For continuous variables, Pearson product-moment
correlation coefficients were calculated. For categorical
variables, the Spearman rank order correlation test was
used. Differences between groups were evaluated by t test
or chi-square test, as appropriate. Univariate analysis
was used in the determination of morphologic variables
significantly associated with and predictive of class IV-
S and IV-G. Comparisons of survival were done by the
Kaplan-Meier method, with differences in survival curves
evaluated by log rank sum testing. Calculations were per-
formed using Statistica® version 6 (Statsoft, Inc., Tulsa,
OK, USA). In all instances, values of P <.05 are consid-
ered statistically significant, but because of small sample
size, values 0.05 < P < 0.10 are retained for reference.
RESULTS
In addition to comparisons of cases diagnosed as class
IV-S and IV-G, ‘pure’ subsets of these 2 classes, in which
≥ 80% of affected glomeruli showed segmental or global
proliferative lesions, respectively, were analyzed in an at-
tempt to refine the morphologic and clinical differences
between the 2 types of lesions (see below).
Evaluation of clinical parameters at biopsy 1
Diffuse global cases have greater proteinuria, and
lower hemoglobins and CH50s (Table 2). They likely have
higher SCrs (P = 0.06) and lower C3s (P = 0.08), as
well (Table 2). In our patients, the diffuse global group
also had a tendency to greater hypertension and higher
DNAs, although these results did not reach significance.
The segmental proliferative cases, by contrast, tended to
have more hematuria: 231 ± 275 versus 115 ± 146 ×
103 rbc/mL, P = 0.07. Complement, whether measured
as CH50 or C3, was inversely correlated with severity of
global proliferative lesions, but not at all with segmental
lesions (Table 2.)
Glomerular lesions
Distribution. Evaluation of the distribution revealed
several important differences between segmental and
global proliferative lesions. First, the percentage of vi-
able glomeruli affected was much higher among the
global proliferative lesions, roughly 95% versus 75%
(Table 3). Perhaps more important, from the standpoint
of pathogenesis, segmental lesions never involved all vi-
able glomeruli, whereas global lesions not infrequently
did (23/31 = 74.2% of patients).
Fibrinoid necrosis. There was no difference in the per-
centage of patients showing glomerular fibrinoid necroses
(46.7% vs. 41.9%). However, among those with fibrinoid
necroses in each group the type of fibrinoid necrosis was
quite different (Table 3). In the segmental proliferative
group, 32.5% of fibrinoid necroses were unaccompanied
by any endocapillary proliferation, as opposed to 0% in
the global proliferative group (P = 0.0015). More impor-
tantly, the percentage of affected glomeruli having fib-
rinoid necroses was much higher among the segmental
proliferative group (13.3 ± 15.3% vs. 5.6 ± 8.0%, P =
0.03). When only cases with “pure” segmental or global
lesions were considered (see below), this disparity in fib-
rinoid necrosis was even greater: 22.3 ± 20.8 versus 7.9 ±
8.9% of affected glomeruli (P = 0.014).
Membranoproliferative features. Membranoprolifer-
ative features in the form of double contours, focal
(13 cases), or diffuse (7 cases), were only found in cases
with global proliferative lesions: 20/31 global cases versus
0/15 segmental cases, P < 0.0001.
Glomerular monocytes/macrophages. These cells,
graded 0 to 4+, were more extensive in global prolifera-
tive than segmental proliferative cases: 1.77 ± .92 versus
0.86 ± 0.77, P = 0.0018. When cases with relatively pure
populations of segmental or global proliferative lesions
are concerned (see below), the disparity between the 2
types is more impressive: 1.95 ± 0.84 versus 0.42 ± 0.53,
P < 0.0001.
Other lesions. By contrast, crescents were infrequent
and were equally distributed between the 2 types of
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Table 2. Clinical parameters at biopsy 1
Class IV-S Class IV-G
Segmental proliferative Global proliferative
15 patients 31 patients Probability
Clinical parameters at biopsy 1
Scr 102 ± 53 148 ± 86 .06
Proteinuria 2.69 ± 2.12 6.27 ± 4.74 .008
Hematuria 231 ± 275 116 ± 146 .07
Hemoglobin 11.0 ± 1.0 9.7 ± 2.1 .03
Hypertension 3/15 = 20% 13/31 = 42% NS
DNA 409 ± 397 656 ± 1069 NS
CH50 42.4 ± 19.4 30.4 ± 15.7 .03
C3 587 ± 151 504 ± 147 .08
Correlations of severity with complement components
r P r P
CH50 .0758 .59 −.4363 .001
C3 .1339 .33 −.3591 .009
Table 3. Summary of parameters related to class IV segmental versus global proliferative lupus nephritis
Class IV-S Class IV-G
Segmental proliferative Global proliferative
15 patients 31 patients Probability
Glomerular parameters
Cases with all glomeruli affected 0/15 = 0% 23/31 = 74.2% <.0001
% of glomeruli affected 75.3 ± 19.6 95.1 ± 8.6 .0001
% of cases with fibrinoid necrosis 7/15 = 46.7% 14/31 = 46.1% NS
% of affected glomeruli with fibrinoid necrosis 13.3 ± 15.3 5.6 ± 8.0 .03
% of fibrinoid necroses in absence of endocapillary proliferation 5/16 gl = 32.5% 0/32 gl = 0% .0015
% of glomeruli with crescents 4.9 ± 6.2 5.9 ± 8.2 NS
% sclerotic glomeruli 7.8 ± 11.0 3.2 ± 5.9 .07
Capillary hyaline depositsa (light microscopy) 1.78 ± .89 2.52 ± .81 .008
Glomerular macrophage/monocytesa .86 ± .77 1.77 ± .92 .0018
% of cases with membranoproliferative features 0/15 = 0% 20/31 = 64.5% <.0001
Parenchymal parameters
Chronic lesions indexa 2.0 ± 1.5 3.3 ± 2.7 .10
Tubular luminal macrophagesa 0.1 ± 0.3 0.6 ± 0.6 .01
Interstitial inflammationa 1.0 ± 0.6 1.6 ± 1.0 .04
Tubulointerstitial activity indexa 5.3 ± 2.4 6.9 ± 3.5 .12
Immunofluorescence parameters
Glomerular capillary IFa 9.0 ± 3.2 12.8 ± 3.5 .001
Glomerular mesangial IFa 9.6 ± 3.2 7.6 ± 3.4 .07
Vascular IFa 1.8 ± 2.2 3.8 ± 3.1 .03
Tubulointerstitial IFa 1.0 ± 1.5 4.0 ± 2.7 .0002
IF Indexa 21.4 ± 5.9 28.2 ± 7.6 .004
IgGa 4.7 ± 1.6 6.9 ± 2.1 .0009
IgAa 2.4 ± 1.7 3.5 ± 2.2 .10
IgMa 2.4 ± 2.6 3.3 ± 2.4 NS
C3a 4.5 ± 1.9 5.6 ± 1.9 .08
C1qa 5.5 ± 2.2 7.9 ± 2.0 .0008
Fibrinogena 1.6 ± 1.3 1.0 ± 1.0 .10
Subendothelial depositsb 1.8 ± 1.1 2.9 ± 0.9 .002
Subepithelial depositsb 1.0 ± 0.8 1.2 ± 0.7 NS
aGraded according to Biopsy index (Table 1).
bGraded 0–3+ as described in [4].
lesions (Table 3). Virtually all viable glomeruli showed
some degree of mesangial increase in both types of le-
sions. There were somewhat more sclerotic glomeruli
among the segmental proliferative cases, but the figure
was low for both types and the results are of only marginal
significance.
Immune deposits
The most striking difference between diffuse segmental
and diffuse global lesions at Bx1 was the markedly greater
immune deposits in the diffuse global group, both on light
microscopy and IF. When only cases of relatively “pure”
segmental or global glomerular lesions are studied (see
below), these differences are accentuated.
Hyaline deposits. Hyaline deposits by light micro-
scopy were greater in the global proliferative group.
Graded on a scale of 0 to 3+ the results were: 2.68 ±
.79 versus 1.42 ± .79, P = 0.0005.
Immune deposits. Global proliferative lesions showed
greater glomerular capillary deposits on IF, graded on a
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Table 4. Univariate analysis of variables associated with classes IV-S and IV-G
Segmental proliferative Global proliferative
Parameter Beta P value Parameter Beta P value
Segmental proliferationa 0.78 0.00000 Global proliferationa 0.83 0.00000
Fibrinoid necrosis without proliferation 0.43 0.003 Gl. hyaline deposits 0.35 0.019
Fibrinoid necrosis with segmental proliferation 0.37 0.01 Gl. Macrophages 0.55 0.01
MPGN features 0.40 0.03
Tubular macrophages 0.37 0.01
Gl. capillary IF 0.60 0.0004
Tubulointerstitial IF 0.52 0.0009
IgG - IF 0.46 0.005
C1q - IF 0.45 0.006
Subendothelial deposits - IF 0.50 0.002
aCriterion on which the division of cases was based. The fact that the betas do not equal 1.0 reflects the admixture of segmental and global lesions in numerous cases.
scale of 0 to 24 (12.7 ± 2.9.5 vs. 8.1 ± 30, P = 0.0007)
(Table 3). Mesangial deposits will be discussed below.
Vascular and tubulointerstitial deposits, as well as overall
deposits, were also much higher in the global proliferative
group.
Perhaps most importantly, definite subendothelial de-
posits, as evaluated semiquantitatively on IF, were simi-
larly much worse among the global proliferative lesions:
2.8 ± .8 versus 1.5 ± 1.1, P = 0.0008. Definite subepithelial
lesions did not differ between the groups.
All of the standard antisera, save fibrinogen, stained
the global proliferative group more intensely, and
these differences reached significance for IgG and C1q
(Table 3). The exception was fibrinogen deposits, which
were worse in the segmental group, although the differ-
ences were not significant: 1.6 ± 1.3 versus 0.9 ± 1.2, P =
0.10.
Mesangial deposits. Mesangial deposits form the ex-
ception to the above instances where immune deposits
are greater and correlated positively with global prolifer-
ative lesions. Mesangial deposits were worse in the seg-
mental proliferative group, but the difference was only
marginally significant (P = 0.07) (Table 3). However,
when only cases with relatively pure lesions were con-
sidered (see below), the differences became significant:
10.1 ± 1.6 for segmental lesions versus 7.3 ± 2.7 for global
ones (P = 0.014).
Strong positive correlations exist between subendothe-
lial deposits and global proliferation (r = .6030, P <
0.0001), but they are strongly negative with segmen-
tal proliferative lesions (r = −.3903, P = 0.009). Ex-
actly reverse correlations are obtained with mesangial
deposits: segmental proliferation, r = .2198, P = 0.12;
global proliferation, r = −2158, P = 0.12, although as
can be seen, the mesangial correlations do not reach
significance.
Parenchymal parameters
In all instances, parenchymal lesions were worse in the
global proliferative group than in the segmental prolifer-
ative group, but only tubular luminal macrophages and
interstitial inflammation, both evidence of disease activ-
ity, reached significance (Table 3). These differences can
be attributed in part to the greater severity of glomerular
involvement among the global proliferative cases.
Univariate analysis of morphologic variables associated
with classes IV-S and IV-G. For each type, class IV-S and
class IV-G, all morphologic variables were submitted to
univariate analysis for their association with one or the
other type (Table 4). Only positive associations are given
because in a categorical system with 2 only possibilities
(here, IV-S or IV-G), associations of any given variable
positive for one type are mirrored by a negative asso-
ciation for the other type). The magnitude of the beta-
value and its probability allow comparison of the relative
contributions of each parameter in the prediction of the
class type, IV-S or IV-G. Variables more or less equally
distributed between the types, such as glomerular obso-
lescence (beta = ± .14, P = 0.37), do not sort significantly.
Evaluation of lesions in “pure” form
Because a great many cases had mixtures of the 2 types
of lesions, muddying and weakening the comparisons
between segmental and diffuse proliferative lesions, we
selected a group of patients in which 80% of more of
the glomeruli involved had either segmental prolifera-
tive lesions (including those with fibrinoid necrosis + seg-
mental lesions) or global proliferative lesions (including
fibrinoid necrosis + global proliferation). Table 5 shows
the results of comparison of “pure” examples of the 2
types of lesions, as well as for mixtures of segmental
and global lesions. For almost all of the parameters, both
clinical and morphologic, the gap in values between the
“pure” IV-S lesions (8 patients) and “pure” IV-G lesions
(22 patients) is greater than for the 2 groups taken as a
whole.
To summarize, in cases in which segmental or prolif-
erative lesions appear more or less in pure form, seg-
mental proliferative lesions show roughly twice as many
fibrinoid necroses/glomerulus as global ones. Second, the
pattern of glomerular immunofluorescence is reversed in
the 2 types. The segmental lesions show predominantly
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Table 5. Comparison of ‘pure’ class IV segmental versus ‘pure’ global proliferative lupus nephritis
‘Pure’ class IV-S Mixed segmental and ‘Pure’ class IV-G Probability
segmental proliferative global proliferative global proliferative ‘pure’ seg vs.
8 patients 16 patients 22 patients ‘pure’ global
Clinical data at biopsy 1
Scr 92.5 ± 26.9 113 ± 54 161.6 ± 96.4 .06
Proteinuria 2.16 ± 1.36 3.5 ± 2.24 7.42 ± 5.13 .008
CH50 50.0 ± 25.8 34.1 ± 21.3 32.1 ± 22.1 .07
C3 671 ± 195 515 ± 205 519 ± 199 .07
anti-DNA 242 ± 148 381 ± 383 778 ± 1497 NS
Glomerular parameters
Cases with all glomeruli affected 0/8 = 0% 10/16 = 62.5% 18/22 = 81.8% .0000
% of glomeruli affected 63.0 ± 19.7 82.5 ± 18.3 97.2 ± 7.4 .0000
% of affected glomeruli with fibrinoid necrosis 23.6 ± 19.1 3.9 ± 8.3 7.9 ± 8.9 .005
% fibrinoid necroses in absence of endocapillary
proliferation 4/13 = 30.7% 1/9 = 11.1% 0/29 = 0% .011
Capillary hyaline deposits (light microscopy)a 1.42 ± .79 2.11 ± 0.83 2.68 ± .79 .0005
Glomerular macrophage/monocytesa 0.42 ± 0.53 1.28 ± 0.89 1.95 ± 0.84 .0000
% of cases with membranoproliferative features 0/8 = 0% 4/16 = 25.0% 15/22 = 68.2% .0000
Immunofluorescence
Glomerular capillary IFa 8.1 ± 3.0 12.1 ± 4.6 12.7 ± 2.9 .0007
Glomerular mesangial IFa 10.2 ± 1.5 8.1 ± 4.6 7.3 ± 2.7 .01
Subendothelial depositsb 1.5 ± 1.1 2.7 ± 1.1 2.8 ± 0.7 .0008
Subepithelial depositsb 1.0 ± 1.0 1.1 ± 0.7 1.4 ± 0.9 NS
Survival from CRX2 at 10 years
68.1% 67.2% 57.3% NS
a Graded according to Biopsy index (Table 1).
b Graded 0–3+ as described in [4].
mesangial deposits and the global proliferative lesions
predominantly capillary deposits. Similarly, the differ-
ences in percentage of affected glomeruli, percentage
showing membranoproliferative features, and the rela-
tive prominence of glomerular macrophages in IV-G le-
sions are all magnified in the comparison between “pure”
lesions.
Mixed segmental and global lesions
Sixteen of the 46 cases had substantial mixtures of
segmental and global proliferative lesions, the means
for which all fell between those of the “pure” lesions
(Table 5). These 16 cases could be subdivided into 8 pre-
dominantly segmental and 8 predominantly global pro-
liferative lesions. For most variables, these cases could be
grouped in order of increasing severity from “pure” seg-
mental, to predominantly segmental, to predominantly
global, to “pure” global. (Example: glomerular hyaline
deposits: 1.4 ± 0.8 → 2.0 ± 0.9 → 2.1 ± 0.8 → 2.7 ±
0.8.) There were no significant differences in any mor-
phologic or clinical parameter between adjacent groups
(data not shown). More importantly, in 55/60 instances
the variables in the predominantly segmental and pre-
dominantly global categories were nearer to the “pure”
lesions of their respective types than to the “pure” lesions
of the opposite type.
Evolution of lesions at biopsy 2
Under the influence of treatment, the majority of
cases reverted to mesangial proliferative (class II) le-
sions, reversion being significantly more frequent with
segmental proliferative lesions than with global lesions
(12/15 cases = 80% vs. 18/31 cases = 58%, P = 0.05).
Among the cases that reverted to mesangial lesions there
was no difference in 10-year survivals (71.1% vs. 76.3%)
between the 2 presenting types.
However, in 16 cases inflammatory activity was not sup-
pressed. There were 7 cases of segmental proliferative
lesions, all originally globally proliferative, and 9 cases
of global proliferative lesions, 6 originally global and 3
cases of segmental proliferative lesions (none originally
“pure”), where the balance had shifted from segmental
to global proliferative lesions.
Of interest, glomerular fibrinoid necroses continued at
a high level among the originally segmental proliferative
cases, but nearly disappeared from the originally global
proliferative cases (21.4 ± 10.0 vs. 0.3 ± 1.2% of affected
glomeruli, P = 0.0035). Immune deposits continued to
be worse in the global proliferative cases, but with the
exception of overall deposits (IF index: 12.8 ± 9.8 vs.
18.7 ± 9.3, P = 0.05) these differences were no longer
significant. The chronicity and tubulointerstitial activity
indices were now significantly worse among those with
global proliferative lesions.
Outcomes
Survival from CRX2. There is no difference in survival
from CRX2 at 10 years between diffuse segmental and
diffuse global lesions at Bx 1, at 10 years: 65.0% segmental
versus 60.4% global, P = 0.53 (Fig. 3). For “pure” cases,
the gap is somewhat wider (68.1% vs. 57.3%), but still
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Fig. 3. Survival from doubling of serum creatinine—Biopsy 1. Survivals are measured from the time of biopsy, but curves begin at the first event,
censoring, or completion.
not significantly different. However, for those who have
not responded to treatment and have persistent prolifer-
ative lesions at Bx2, there is likely a difference in survival
at 10 years at Bx2: 63.6% segmental versus 0% diffuse
(Fig. 4). Despite the dramatic difference, the results are
only marginally significant, P = 0.08, owing to small sam-
ple size, 11 and 9 patients, respectively.
Renal relapse. There was no significant difference be-
tween the 2 groups in terms of renal relapse, 30.7% of
IV-S and 42.8% of IV-G patients having one or more re-
lapses. Relapse was attended by a high rate of CRX2 in
both groups (3/4 = 75% in IV-S and 8/12 = 66.7% in
IV-G), as described previously [5].
DISCUSSION
There are 3 studies to which our data may be more
or less directly compared: (1) Najafi et al [2], who were
in substantial part responsible for the division of class
IV-S and IV-G; (2) Mittal et al [8], using the new clas-
sification; and (3) Yokoyama et al [9], using the new
classification and offering clinical and outcome data but
only limited morphologic information. These studies are
compared in Table 6. As can be seen, there is consen-
sus that the clinical manifestations are worse with global
proliferative lesions, and that hyaline deposits/wire loops
and subendothelial deposits are worse with global le-
sions, whereas fibrinoid necroses/fibrin thrombi are worse
with segmental lesions. It is probably fair to say that
activity and chronicity indices are generally worse with
global proliferative lesions, a notable exception being the
greater chronicity index in segmental lesions in the series
of Najafi et al [2].
Regarding outcomes, the best series with which to com-
pare our results is that of Najafi et al [2], that of Mittal et al
[8] suffering from limited follow-up (38 and 55 months),
and that of Yokoyama et al [9] having only limited num-
bers of patients (6 IV-S and 17 IV-G). The principal dif-
ference between the series of Najafi et al [2] and our own
is the much higher NIH chronicity indices among their
segmental patients than among our own, 3.8 ± 2.6 versus
1.7 ± 1.2 (a gap too large to be explained by interob-
server variation), which would help to explain the worse
outcome of IV-S patients in their series. It is clear, how-
ever, that the relative outcome of segmental versus global
proliferative lesions is an issue that remains unresolved.
In addition to these reports [2, 8, 9], there have been
prior reports describing patients resembling our patients
with segmental proliferative lesions [10, 11]. They had
severe lupus nephritis but, as with our patients, mesangial
deposits predominated and there were only mesangial
deposits and few or no subendothelial deposits.
Although in our experience there is no difference in
survival between segmental and global proliferative le-
sions at first biopsy, those with global proliferative lesions
at Bx2 after treatment all eventually went on to double
their SCr. However, clearly these patients all represent a
failure to respond to treatment, so their poor outcomes
should come as no surprise.
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Fig. 4. Survival from double of serum creatinine. Patients with persistent segmental or global proliferative lesions at biopsy 2. Survivals are measured
from the time of biopsy, but curves begin at the first event, censoring, or completion.
Table 6. Comparison of studies dealing with distinctions between class IV-S (S) and IV-G (G) lupus glomerulonephritis
Observation Present study Najafi et al [2] Mittal et al [8] Yokoyama et al [9] Consensus
Clinical
Hypertension G > S G > S G > Sa G > S
Proteinuria G > Sb G > Sa G > Sa G ≈ S G > S
Hematuria S > Ga
SCr G > Sa G > S G > Sb G ≈ S G > S
DNA G > S G > S G > S
CH50 G < Sb S < G G < S
C3 G < Sa G < Sb S < G
C4 G < S G < S S < Ga
Hemoglobin/Hct G < Sa G < S G < S
Morphologic
Capillary hyaline deposits/wire loops G > Sb G > Sb G > Sa G > S
Subendothelial deposits—IF or E/M G > Sb G > S G > S
Fibrinoid necrosis/fibrin thrombi S > Gb S > G S > Gb S > G
Interstitial inflammation G > Sb S > Gb
Interstitial fibrosis G > S G ≈ S S > G
Activity Index G > S G > S S > G G > S
Chronicity Index G > Sa S > Ga G > S G > S
Outcomes
1st biopsy G ≈ S S < Ga G ≈ S S < G
2nd biopsy G < Sa
a0.05 < P < 0.10.
bP < 0.05.
A question of perhaps more interest is whether the seg-
mental proliferative lesions have a different pathogenesis
than the global proliferative lesions, as has indeed been
proposed by previous authors [2, 9, 11]. The basic differ-
ences between the 2 types are detailed in Table 7.
In our experience, the global proliferative lesions be-
have as an immune complex glomerulonephritis, as we
have traditionally conceived of lupus glomerulonephri-
tis as a whole. Capillary deposits predominate and
there is a positive correlation between the extent of
subendothelial deposits and the severity of morpho-
logic and clinical manifestations, with additional corre-
lations with depression of CH50 and C3. Najafi et al [2]
found similar features in their category IV lesions, with
much more extensive wire loops and hyaline thrombi
and massive deposits, and lower serum C3s. Further,
the global proliferative lesions frequently show involve-
ment of all viable glomeruli and membranoproliferative
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Table 7. Basic differences between segmental proliferative and global proliferative class IV lupus nephritis
Segmental proliferative Global proliferative
Involvement of all viable glomeruli None 74.2% of cases (P <.0001)
Membranoproliferative features None 64.5% of cases (P <.0001)
Glomerular monocyte/macrophages Minimal Prominent
Fibrinoid necrosis—% affected gl. Significantly morefrequent Less frequent
Fibrinoid necrosis in absence of endocapillary proliferation Yes No
Glomerular IF Mesangial IF predominates Capillary IF predominates
Glomerular subendothelial deposits Negative correlation Positive correlation
Serum CH50 and C3 No correlation Negative correlation
features, neither of which is true for segmental prolifera-
tive lesions.
By contrast, the segmental proliferative lesions tended
to show a negative correlation with glomerular suben-
dothelial deposits and had a definite predominance of
mesangial staining over capillary wall staining. Further,
they showed no correlation with serum CH50 and C3
levels.
Fibrinoid necrosis was much more prominent among
the segmental proliferative lesions. Although the per-
centage of cases with any degree of fibrinoid necrosis
was similar between segmental and global proliferative
lesions (46.7 vs. 46.1%), the types and distribution of
fibrinoid necroses were strikingly different (Table 3).
Fibrinoid necroses without associated endocapillary pro-
liferation occurred with some frequency in segmental
proliferative cases, but never in global proliferative cases
(P = 0.0015). The percentage of affected glomeruli with
fibrinoid necroses was markedly higher among segmen-
tal proliferative cases: 13.3 ± 17.3% versus 5.6 ± 8.0%,
P = 0.03. This disparity was even greater among cases
with more or less “pure” segmental lesions (Table 5),
and was even more striking after treatment, when fibri-
noid necroses basically disappeared from patients with
originally global proliferative lesions but persisted at
high levels among those with originally segmental pro-
liferative lesions. Similarly, Najafi et al [2] noted an in-
creased frequency of fibrin thrombi and segmental fibrin
staining on IF among their category III (≥50%) lesions
and, interestingly, a greater frequency of hematoxylin
bodies among these cases than in their category IV
cases.
All of these findings cast doubt on the pathogenesis of
the segmental proliferative lesions as a classic immune
complex disease. (We are not the first to express these
doubts [2, 9, 10], but rather, simply the first to system-
atically explore and codify the evidence for them.) The
process in segmental lesions seems to be one that af-
fects glomeruli not only segmentally, but focally as well,
never in our experience affecting all glomeruli, as global
proliferative lesions frequently do. In this respect, these
cases behave much like ANCA-related and anti-GBM
glomerulophritides, which begin focally although they
may eventually come to involve all the glomeruli.
The question may be raised as to what might be the
pathogenesis of these segmental lesions. The resemblance
of the segmental proliferative lesions to ANCA-related
glomerulonephritis, with their emphasis on fibrinoid
necrosis, suggests ANCA as a possible mechanism. It is
known that 15% to 20% of patients with SLE have de-
tectable ANCA [12]. Indeed, isolated cases have been
reported in which ANCA seems clearly to be implicated
as a major pathogenetic factor [13–15]. Some authors
have found a correlation between the presence of ANCA
and crescents [16], an association between p-ANCA
and nephritis [17], and association of anti-cathepsin G-
ANCA with lupus nephritis [18]. However, several other
studies have failed to find a correlation with lupus nephri-
tis [19–22]. Nonetheless, only Chin et al [17] have specif-
ically looked at class IV lesions (their study finding a
positive correlation with p-ANCA), and no study has sub-
divided class IV lesions into segmental versus global pro-
liferative lesions, so the jury is still out as to a possible
connection between ANCA and segmental proliferative
lesions.
Another possibility to be considered is the possible role
of antiendothelial cell antibodies (AECAs) in these le-
sions. One study has found a correlation between AECAs
and histologic evidence of active disease and particularly
glomerular crescents [23], and another with the presence
of glomerular thrombi [24]. However, studies in this area
are limited and none have looked specifically at the issue
at hand. Similarly, it is known that the overall Th1/Th2
lymphocyte ratio is higher in patients with class IV lupus
nephritis than in patients with class V or minor glomeru-
lar lesions [25]. Further, the ratio of the Th1-related cy-
tokines [IFN-c and interleukin (IL)-12] compared to the
Th2 cytokines (IL-4 and IL-10) is increased in patients
with class IV lupus nephritis, compared with class V le-
sions [26]. It is also known that there are differences in
the genotype of IFN-c between patients with class IV and
class V lupus nephritis [27]. However, this represents the
extent of specific morphologic correlations in this area to
date.
Finally, the possibility remains open that yet other
mechanisms might be operative here, likely in addi-
tion to the standard immune complex disease. Totally
immunonegative necrotizing glomerulonephritis, in the
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absence of ANCA, has been reported in lupus [28]. In
addition, it is known that patients with lupus may have
nephrotic-range proteinuria in the absence of capillary
wall deposits, and sometimes even in the absence of
mesangial deposits [29, 30]. Although it is possible that
all of the patients described in these studies had coinci-
dent minimal change nephropathy or FSGS, the possibil-
ity must be kept in mind that other mechanisms, perhaps
cytokine- or lymphokine-related, are coming into play.
It should be kept in mind that if indeed there are dif-
ferent pathogenetic mechanisms involved in class IV lu-
pus nephritis, they are likely frequently at play in varying
degrees within a given patient. Sixteen of our 46 patients
showed substantial admixtures of lesions, with results sug-
gesting a more or less continuous spectrum of lesions.
(However, since the predominantly segmental and pre-
dominantly global types more closely resembled their re-
spective “pure” counterparts than the opposite types, the
division in the present classification simply on the basis
of which type of lesion predominates seems entirely ap-
propriate.)
CONCLUSION
Unfortunately, the data in our series offer no way of
distinguishing among the different pathogenetic possi-
bilities because the appropriate studies are not available.
However, we feel that the data we have presented sup-
port the notion that while global proliferative lesions are
likely immune complex-related, as has been thought for
lupus nephritis in general, the segmental proliferative le-
sions have distinctive characteristics pointing to another
possible etiology. Should this be the case, it is to be hoped
that a more specific therapy may ultimately be developed
for these lesions.
Reprint requests to Gary S. Hill, M.D., 26 rue Edouard Jacques, 75014
Paris, France.
E-mail: garyhillparis@aol.com
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